Kenview Rebounds Amid Controversial Tylenol Comment

about 1 month ago

Tim Stenebeck

"We're looking at shares of Kenview. ... this is us looking at the stock that is recouping some of its losses that we saw yesterday. The big news yesterday, President Trump saying that pregnant women should avoid taking Tylenol ... we're hearing news today from scientists and from others on Wall Street saying that there is no scientific evidence to support this being the case. And so we are seeing a rebound in the stock today and trading up as much as 7.2% earlier. So now up about 2%."

Kenview (KVUE) is noted for recovering from recent losses attributed to negative headlines regarding Tylenol. Improved sentiment following clarification from scientists has resulted in an intraday rebound, making it a point of interest for investors.

Related Stocks